AlzGene - Gene overview of all published AD-association studies for IDE
Back Search Methods Disclaimer Credits
 Gene: IDE  (INSULYSIN)  Entrez Gene    View on PDGene
 Protein: insulin-degrading enzyme  (insulysin; insulinase)  ProteinLink
 Chromosome: 10   (View: 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  X  Y  MT)
 Status: Updated 18 April 2011
Meta-Analysis
1. Case-Control Studies (by ethnic group)
      AD Cases Normal Controls    
Study Population Source # Polys # Subjects
(% women)		 DX Onset Age
(range)		 Age
(range)		 # Subjects
(% women)		 Age
(range)		 Result Comment
 Caucasian
Abraham, 2001
 UK (Cardiff) CL  5  (detail)  133
(-)		M72.5 + 6.5
(-)		-135
(-)		78.2 + 7.2
(-)		Negative
Abraham, 2001
 Overlaps with
Carrasquillo, 2010 (USA-JS)		 CL  5  (detail)  95
(-)		C79 + 9
(-)		-117
(-)		85.1 + 7.9
(-)		Negative
Abraham, 2001
 USA (WashU) CL  2  (detail)  86
(-)		C74.5 + 6.2
(-)		-94
(-)		81 + 8.1
(-)		Negative
Bjoerk, 2006
 Sweden (Set 1) CL  3  (detail)  423
(61%)		M79.3 + 7.2
(-)		-464
(58%)		65.8 + 6.4
(-)		Positive
Bjoerk, 2006
 UK (Set 2) CL  3  (detail)  356
(59%)		N80.8 + 8
(-)		-110
(46%)		77.1 + 6.4
(-)		Positive
Bjoerk, 2006
 Overlaps with
Prince, 2003		 CL  3  (detail)  490
(61%)		M76.7 + 7.1
(-)		-406
(67%)		74.4 + 8.8
(-)		n.a.
Blomqvist, 2004
 Overlaps with
Prince, 2003		 CL  2  (detail)  290
(70%)		C75.6 + 7.1
(-)		79.8 + 6.4
(-)		--Positive
Boussaha, 2002
 France CL  2  (detail)  202
(-)		C67.1 + 10.2
(-)		-186
(-)		68.6 + 12.2
(-)		Negative
Carrasquillo, 2010
 USA & Europe CL  17  (detail)  3529
(62%)		M-77.6 + 7.9
(-)		3441
(55%)		77.2 + 7.3
(-)		Positive
Cellini, 2005
 Italy CL  2  (detail)  302
(-)		C68 + 5.1
(-)		-164
(-)		-Negative
Corder, 2008
 Overlaps with
Prince, 2003		 CL  4  (detail)  938
(-)		U--397
(-)		-n.a.
Cousin, 2009
 France CL  1  (detail)  428
(-)		C64.9 + 9.9
(-)		-475
(-)		66.2 + 10.8
(-)		Negative
Edland, 2003
 Overlaps with
Abraham, 2001		 CL  5  (detail)  80
(71%)		C--118
(69%)		-Negative
Ertekin-Taner, 2004
 Overlaps with
Carrasquillo, 2010 (USA-JS)		 CL  3  (detail)  109
(-)		C--109
(-)		-Trend
Ertekin-Taner, 2004
 Overlaps with
Carrasquillo, 2010 (USA-RS)		 CL  3  (detail)  188
(-)		C--188
(-)		-Negative
Feuk, 2005
 Scotland CL  9  (detail)  121
(-)		C52.4 + 6.8
(-)		57.8 + 6.3
(-)		152
(-)		58.2 + 9.8
(-)		Negative
Giedraitis, 2009
 Sweden (ULSAM) CL  4  (detail)  86
(0%)		C80.2
(72-85)		-404
(0%)		81.8
(80-84)		Negative
Grupe, 2006
 Overlaps with
Nowotny, 2005		 CL  0  422
(-)		C--382
(-)		-Negative
Li, 2008
 Canada CL  4  (detail)  753
(58%)		C71.9 + 8.5
(-)		77.8 + 8.6
(-)		736
(64%)		73.4 + 7.9
(-)		Negative
Liang, 2007
 USA CL  1  (detail)  483
(63%)		C71.8 + 6
(-)		76.5 + 6.5
(-)		879
(58%)		72 + 6.3
(-)		Positive
Mueller, 2006
 Germany CL  27  (detail)  444
(60%)		C69.2 + 9.4
(-)		-269
(59%)		66.4 + 12.7
(-)		Trend
Nowotny, 2005
 UK I (mixed) CL  3  (detail)  376
(76%)		C75.8 + 7.1
(-)		-384
(75%)		76.5 + 6.3
(-)		Negative
Nowotny, 2005
 UK II (IAH) CL  2  (detail)  175
(67%)		N76.2 + 6.8
(-)		81.5 + 6.6
(-)		125
(49%)		78.2 + 8.6
(-)		Positive
Nowotny, 2005
 USA (UCSD) CL  2  (detail)  246
(46%)		C72.1 + 6.3
(-)		-360
(64%)		78.6 + 7.6
(-)		Negative
Nowotny, 2005
 USA (WashU) CL  17  (detail)  420
(62%)		C76.2 + 6.8
(-)		-388
(60%)		77.7 + 7.4
(-)		Negative
Ozturk, 2006
 USA CL  3  (detail)  1012
(67%)		M72.3 + 6.3
(-)		76.6 + 5.7
(-)		771
(61%)		75.2 + 5.6
(-)		Negative
Prince, 2003
 Scotland CL  13  (detail)  121
(42%)		C52.4 + 6.8
(-)		57.8 + 6.3
(-)		152
(46%)		58.2 + 9.8
(-)		Negative
Prince, 2003
 Sweden CL  13  (detail)  527
(60%)		M73.2 + 8
(-)		78.2 + 7.1
(-)		511
(63%)		79.9 + 5.2
(-)		Negative
Reiman, 2007
 Overlaps with
Carrasquillo, 2010 (USA)		 CL  4  (detail)  861
(-)		M-74.9 + 6.6
(-)		550
(-)		77.4 + 7.3
(-)		Negative
Vepsalainen, 2007
 Finland CL  4  (detail)  370
(69%)		C72 + 7
(43-90)		-454
(61%)		70 + 5
(60-87)		Positive
Vepsalainen, 2009
 Overlaps with
Vepsalainen, 2007		 CL  2  (detail)  379
(69%)		C72 + 7
(43-90)		-456
(61%)		70 + 5
(60-87)		n.a.
Zou, 2010
 Overlaps with
Carrasquillo, 2010 (USA-AUT)		 CL  12  (detail)  526
(60%)		N-81
(60-105)		324
(42%)		76.2
(60-98)		Positive
Zou, 2010
 Overlaps with
Carrasquillo, 2010 (USA-JS)		 CL  12  (detail)  575
(62%)		C-78.1
(61-95)		574
(60%)		78
(60-100)		Positive
Zou, 2010
 Overlaps with
Carrasquillo, 2010 (USA-RS)		 CL  12  (detail)  502
(63%)		C-80.1
(61-104)		1298
(54%)		78.6
(74-99)		Positive
Zou, 2010
 Overlaps with
Carrasquillo, 2010 (USA-NCRAD)		 CL  1  (detail)  687
(65%)		M--203
(62%)		78.3 + 8.9
(61-99)		Negative
 Asian
Bian, 2004
 China CL  4  (detail)  210
(-)		C74.5
(-)		-200
(-)		72
(-)		Negative
Kuwano, 2006
 Japan CL  12  (detail)  1526
(72%)		C73.4 + 6.6
(-)		-1666
(60%)		73 + 7.8
(-)		Negative
Sakai, 2004
 Japan CL  2  (detail)  248
(70%)		C-74.4 + 9.6
(-)		163
(72%)		72.9 + 7.6
(-)		Negative
Zuo, 2008
 China CL  3  (detail)  357
(57%)		C62.2 + 4.3
(-)		70.3 + 9.8
(-)		331
(62%)		66.6 + 8.5
(-)		Positive
 Hispanic
Reitz, 2010
 USA PO  14  (detail)  160
(-)		C--294
(-)		-Positive
 Other/Mixed
Marlowe, 2006
 USA (HAAS) PO  4  (detail)  179
(-)		C--648
(-)		79.8 + 5.3
(-)		Negative
Contact us if you are an author of an association study regarding this gene and do not find your study in this table or find errors in the representation of your study details.
2. Family-Based Studies (by ethnic group)
      Affecteds Unaffecteds    
Study Population # Polys # Families # Subjects
(% women)		 DX Onset Age
(range)		 Age
(range)		 # Subjects
(% women)		 Age
(range)		 Result Comment
 Caucasian
Liang, 2007
 USA  1  (detail)  7301521
(67%)		C72.9 + 6.4
(-)		80.1 + 7.1
(-)		974
(56%)		69.9 + 11.2
(-)		Positive
 Other/Mixed
Ertekin-Taner, 2004
 USA  3  (detail)  24-M----Positive
Contact us if you are an author of an association study regarding this gene and do not find your study in this table or find errors in the representation of your study details.
Source:  Source of case population -> “CL” (clinic-based), “PO” (population-based), or “CO” (community-based).
# Polys:  Number of polymorphisms tested per gene and per sample.
Onset Age and Age:  Mean or median age at onset or examination, respectively.
DX:  Criteria used to determine AD diagnosis ->  "C" (clinical AD diagnosis), "N" (neuropathological AD diagnosis), "M" (mixed, i.e. AD sample contains both clinical and neuropathological cases), "U" (unknown).
Result:  Overall conclusion reached by authors of the original publication (“positive” usually indicates significant (P<0.05) association in at least one of the performed analyses, and “negative” indicates no evidence for significant association, while “trend” indicates results in between); results obtained in duplicate or largely overlapping samples are listed as "n.a.".
(-) :  Either no data provided or in case of overlap, data included in original study.
AlzGene Recent Updates
AlzGene Top Results
Top Results Details
1. APOE_e2/3/4
2. BIN1
3. CLU
4. ABCA7
5. CR1
6. PICALM
7. MS4A6A
8. CD33
9. MS4A4E
10. CD2AP
AlzGene Stats
Studies: 1395
Genes: 695
Polymorphisms: 2973
Meta-analyses: 320
Cure Alzheimer's Fund
Proud supporter of the AlzGene database.
Michael J. Fox Foundation
The PDGene database is supported by a grant from The Michael J. Fox Foundation in partnership with the Alzheimer Research Forum.

NCRAD
The National Cell Repository for Alzheimer Disease seeks to recruit 1,000 families with two or more living brothers or sisters who have been diagnosed with late onset Alzheimer’s disease.
ALSGene
AlzGene
MSGene
PDGene
SZGene
An up-to-date collection of all published genetic association studies.